The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis

Brain

Volumn 124, Issue 9, 2001, Pages 1743-1753

  Lindberg, Raija L P ^a   De Groot, Corline J A ^b   Montagne, Lisette ^b   Freitag, Peter ^a   Van Der Valk, Paul ^b   Kappos, Ludwig ^a   Leppert, David ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain tissue; Matrix metalloproteinases; Multiple sclerosis; Real time polymerase chain reaction; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE B; INTERLEUKIN 2; LYMPHOTOXIN; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; MULTIPLE SCLEROSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TISSUE NECROSIS; TRANSCRIPTION REGULATION; WHITE MATTER;

EID: 0034842248     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/124.9.1743     Document Type: Article

References (54)

1. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke
2. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS
3. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression
4. Matrix metalloproteinases in multiple sclerosis. Targets of therapy or markers of injury?
5. Tumor necrosis factor alpha mRNA expression in early multiple sclerosis lesions. Correlation with demyelinating activity and oligodendrocyte pathology
6. Macrophage inflammatory protein-1α (MIP-1α), MIP-1β, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions
7. The adhesion molecule and cytokine profile of multiple sclerosis lesions
8. Multiple sclerosis: Magnetization transfer histogram analysis of segmented normal-appearing white matter
9. Matrix metalloproteinases degrade myelin basic protein
10. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor
11. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
12. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
13. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
14. A novel method for real time quantitative RT-PCR
15. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
16. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases
17. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline
18. Pathogenesis of multiple sclerosis
19. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790
20. Tumor necrosis factor identified in multiple sclerosis brain
21. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes
22. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis
23. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis
24. Matrix metalloproteinases in inflammatory demyelination. Targets for treatment
25. Tumor necrosis factor alpha and lymphotoxin stimulate human myeloblastic leukemia cell (ML-1) invasion through a reconstituted basement membrane (Matrigel) with concomitant induction of 92 kDa gelatinase secretion
26. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study
27. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study
28. T cell gelatinases mediate basement membrane transmigration in vitro
29. IFN beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
30. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis
31. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: Association with blood-brain barrier damage and neurological sequelae
32. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis
33. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
34. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions
35. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α
36. Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta
37. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states
38. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
39. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells monocytes/macrophages in bronchiectasis
40. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein
41. Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque
42. Tumor necrosis factor-α induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window
43. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
44. Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
45. Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
46. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS
47. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
48. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
49. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI study
50. The matrix metalloproteinase family
51. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions
52. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane
53. The potential use of MMP inhibitors to treat CNS disease
54. Matrix metalloproteinases diseases of the CNS